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Tuberculosis (TB) is the leading non-obstetric cause of maternal 
death in South Africa (SA), and is often difficult to diagnose during 
pregnancy.[1-3] Ante- and intrapartum transmission of Mycobacterium 
tuberculosis occurs haematogenously via the placenta or when 
infected amniotic fluid is aspirated or ingested during delivery, 
and may result in congenital TB. Although congenital transmission 
is uncommon, it is more likely to occur when the mother has 
primary TB or disseminated disease.[4] Postnatal TB transmission 
via respiratory airborne spread is more common when she has 
adult-type (cavitary) pulmonary TB.[4] The screening investigations, 
diagnosis and treatment of term and preterm neonates with possible 
or confirmed congenital or postnatal TB are the same, independent 
of the timing of M. tuberculosis infection.
TB in pregnancy is associated with unfavourable outcomes for 
both mothers and their infants, with double the risk of preterm 
delivery (<37 weeks’ gestational age) and/or low birthweight (LBW) 
(<2 500 g) compared with healthy mothers.[5] The diagnosis of TB 
in neonates is challenging, particularly in preterm and LBW infants, 
in whom respiratory symptoms due to hyaline membrane disease or 
other causes can be difficult to distinguish from pneumonia caused 
by TB. Neonates born to mothers with TB, i.e. TB-exposed neonates, 
can be asymptomatic, clinically well, or present with nonspecific 
signs such as fever, respiratory distress, abdominal distension from 
ascites and/or hepatosplenomegaly, or even obstructive jaundice. [6-8] 
Without preventive therapy, up to 50% of TB-exposed infants 
(<12 months of age) will develop TB disease, with disseminated or 
progressive pulmonary disease in 30% of these cases.[9] Appropriate 
assessment and management of the TB-exposed neonate is therefore 
essential, given the high risk of progression from TB infection to TB 
disease in this population.
In 2019, the SA National Department of Health (NDoH) published 
updated guidelines for the prevention of mother-to-child 
transmission of communicable diseases.[10] These guidelines included 
an algorithm describing the management of any TB-exposed neonate 
born to a mother who may pose a TB infectious risk to her newborn 
baby. This was defined as a mother with TB diagnosed in the 
last 2 months of pregnancy or a mother who has not responded 
to TB treatment or whose sputum remains positive for acid-fast 
bacilli (AFB). The focus of the NDoH guidance is mainly on term 
neonates born at midwife obstetric units, and it recommends referral 
of all symptomatic TB-exposed neonates (respiratory rate >60/
min, difficulty in breathing, feeding problems, poor weight gain, 
abdominal distension, enlarged liver/spleen and/or jaundice) to 
hospital for evaluation for TB. The NDoH guideline does not 
provide recommendations on the hospital-based investigation and 
management of these referred, symptomatic, TB-exposed neonates, 
nor does it provide an approach to evaluation of hospitalised preterm 
and LBW TB-exposed neonates. Investigations for and treatment of 
TB are similar for term and preterm neonates, but a low threshold 
for investigating preterm TB-exposed infants is essential owing to 
frequent atypical presentations and a high risk of progression of 
disease.[4]
No standard approach exists for the evaluation of hospitalised 
symptomatic term and symptomatic or asymptomatic preterm and/
or LBW TB-exposed neonates, with practices varying greatly.[7] 
Given the diagnostic challenges, we use a case study to illustrate 
the different TB screening investigations available for TB-exposed 
neonates and the interpretation thereof. Furthermore, we propose a 
hospital-based evaluation algorithm for the TB-exposed neonate to 
complement the NDoH guidelines.
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Case study
A 30-year-old woman presented to Tygerberg Hospital, Cape Town, 
SA, in spontaneous preterm labour (SPTL) with prolonged rupture 
of membranes (PRoM), at an estimated 33 weeks’ gestation. She 
had received no antenatal care, and admission screening tests 
for HIV and syphilis were negative. She gave birth to a preterm, 
LBW (2 252  g) male infant via normal vertex delivery. Although 
the neonate appeared well after delivery, he was admitted for 
investigation of possible neonatal sepsis because of the maternal 
risk factors of SPTL and PRoM, and was initiated on prophylactic 
ampicillin and gentamicin. While visiting her baby, the mother 
complained of a persistent cough and night sweats. She reported 
submitting a sputum sample for TB investigation at her local clinic a 
few days before delivery. She had previously been treated for drug-
susceptible pulmonary TB (DS-TB) in 2014 and 2016, but reported 
treatment interruption after 3 months in the latter episode. Her 
current sputum samples were both smear-negative for AFB with 
M.  tuberculosis cultures pending. Her chest radiograph showed 
cavitary lung disease with fibrosis.
Given the high risk of perinatal TB disease in this hospitalised 
preterm LBW infant, born to a mother with current symptoms 
of TB and a history of previously interrupted TB treatment, a 
decision was made to assess the neonate for TB. The TB evaluation 
included clinical examination, radiological imaging and laboratory 
investigations. The findings on clinical examination and the chest 
radiograph were normal. Two gastric aspirates were sent for smear 
microscopy for AFB, Xpert MTB/RIF Ultra (Xpert Ultra) and 
mycobacterial culture. The smear microscopy for AFB was negative, 
but Xpert Ultra was trace positive for M. tuberculosis complex 
on one gastric aspirate taken on day 2 after birth (rifampicin 
susceptibility testing was unsuccessful). After consultation with 
paediatric infectious disease experts, an abdominal ultrasound scan 
was requested to investigate for possible hepatic lesions suggestive of 
TB; this was normal. Subsequently, a decision was made not to treat 
this asymptomatic, TB-exposed neonate, but rather to give him TB 
preventive therapy (TPT) (as low amounts of M. tuberculosis DNA in 
gastric aspirates may represent bacilli ingested in utero or at birth). 
In the light of the normal findings on clinical examination and the 
normal chest radiograph and abdominal ultrasound scan, isoniazid 
was commenced as TPT on day 5 after birth at a dose of 10 mg/kg/d. 
Isoniazid therapy was deemed sufficient to eradicate the ingested 
bacilli and prevent TB disease progression. The infant was discharged 
into the care of his mother, who was restarted on DS-TB treatment 
by the local clinic based on her clinical features and the infant’s Xpert 
Ultra results. BCG vaccination was deferred until after completion of 
TPT. Regular outpatient follow-up visits were scheduled to monitor 
the infant’s wellbeing and growth, with several dose adjustments 
needed (a three-fold increase in isoniazid dose from initiation to 
completion of TPT). All M. tuberculosis cultures from the neonate’s 
specimens were negative. The infant and mother remained well, 
and both had successfully completed TPT and DS-TB therapy, 
respectively, at the 6-month visit. BCG vaccination was given after 
completion of TPT and no tuberculin skin test (TST) was performed.
This case study illustrates an asymptomatic but preterm and LBW 
TB-exposed neonate who was considered to be at high risk of TB 
infection because of the history of untreated TB in a symptomatic 
mother. Clinical examination and screening investigations for TB in 
this neonate were negative, except for one trace-positive Xpert Ultra 
gastric aspirate result, which probably reflected TB bacilli ingested 
at birth. The neonate was accordingly assessed as not having TB 
disease and was therefore commenced on a course of TPT only, with 
regular clinical follow-up to evaluate for the development of any TB 
symptoms and/or signs. The positive Xpert Ultra result in the neonate 
facilitated rapid initiation of TPT, and TB disease was successfully 
prevented. In addition, the laboratory confirmation of TB led to the 
rapid recommencement of TB treatment in the mother, who had a 
history of chronic symptoms and a chest radiograph with bilateral 
upper-lobe adult-type cavitary TB.
Ethics approval and informed consent
Written informed consent for the publication of this case report was 
obtained from the patient, and ethical approval was obtained from 
the Stellenbosch University Faculty of Medicine and Health Sciences 
Undergraduate Research Ethics Committee (ref. no. UC19/08/032).
Discussion and recommendations
The 2019 NDoH guidance[10] provides recommendations for the 
management of asymptomatic TB-exposed infants and instructs 
that symptomatic neonates be referred to hospital for TB evaluation. 
Information on how this evaluation should be conducted is lacking, 
however, with no guidance offered on how to manage preterm and 
LBW TB-exposed neonates, which we suggest should be included 
in the hospital-based evaluation of a TB-exposed neonate. To our 
knowledge, no standard approach for the evaluation of symptomatic 
TB-exposed neonates exists. A review by Mittal et al.[7] tried to 
capture the varying approaches to the management of TB-exposed 
neonates, which are mainly based on expert opinion.
To address the lack of clinical guidance for in-hospital management 
of TB-exposed neonates, we propose an evaluation algorithm that 
includes both symptomatic term neonates and asymptomatic and 
symptomatic preterm and LBW neonates (Fig. 1). At Tygerberg 
Hospital, an academic referral hospital in Cape Town, SA, all 
symptomatic TB-exposed neonates, including all TB-exposed preterm 
and/or LBW neonates, are evaluated for TB disease with a minimum 
of two gastric aspirates for AFB smear microscopy, mycobacterial 
culture and Xpert Ultra, and a chest radiograph. Depending on the 
clinical symptoms and signs, other directed investigations may also 
be appropriate (Fig. 1 and Table 1).
Once TB disease has been excluded in a symptomatic term neonate 
born to a mother with infectious TB (newly diagnosed, treated for 
<2 months, still culture-positive or AFB smear-positive), TPT is 
initiated. We also make use of the same strategy when managing 
asymptomatic or symptomatic preterm or LBW neonates born to 
an infectious mother with TB. The World Health Organization 
(WHO) recommends either 6 months of isoniazid or 3 months 
of isoniazid plus rifampicin (Tables 2 and 3) for the prevention of 
DS-TB.[11] Regular (monthly) follow-up visits should be scheduled 
for all TB-exposed neonates to record weight gain and adjust the TPT 
medication doses, assess infants for new TB symptoms or signs, and 
if these are present, re-evaluate for TB disease.
In symptomatic, preterm or LBW infants born in SA where TB 
evaluation confirms or is suggestive of TB disease, a four-drug 
TB treatment should be started immediately (Tables 2 and 3). As 
recommended by the WHO, children with probable or confirmed 
pulmonary TB or TB peripheral lymphadenitis and/or children with 
extensive pulmonary disease, living in settings where the prevalence 
of HIV is high and/or the prevalence of isoniazid resistance is 
high, should be treated with a four-drug regimen for 2 months 
followed by a two-drug regimen for 4 months.[12] Owing to the 
difficulty in monitoring for ethambutol-induced ocular toxicity 
in neonates, ethionamide is sometimes preferred as the fourth 
drug, with the added advantage of good central nervous system 
726       August 2021, Vol. 111, No. 8
IN PRACTICE
penetration. [13,14] The continuation phase of isoniazid and rifampicin 
(usually 4 months) may be prolonged to 7 months depending on the 
infant’s initial disease severity and/or clinical response.[12]
In the case of asymptomatic neonates whose mothers with TB are 
no longer infectious (i.e. on effective treatment for >2 months and 
preferably sputum culture-negative), we advise that these neonates 
undergo a clinical examination; if the findings are normal, no TB 
screening tests are performed and no TPT is required. BCG should 
be administered immediately after birth. The neonate should be 
followed up regularly to monitor weight gain and evaluated for 
new TB symptoms or signs, which, if present, should lead to 
TB evaluation. The mother and/or other household members’ 
TB treatment progress should be monitored, as the infant may 
be re-exposed if the TB-infected adult/s are lost to follow-up or 
experience treatment failure.
BCG, HIV and drug-resistant TB considerations for 
TB-exposed neonates
BCG vaccination should be deferred until 2 weeks after completion 
of TPT or anti-TB treatment, as anti-TB medications may kill the 
live BCG vaccine. The rationale for administering BCG following 
preventive or TB treatment is to protect against disseminated 
TB disease in the case of TB re-exposure.[15] BCG is routinely 
administered at birth to neonates in SA, including those born to 
women living with HIV, often prior to receipt of the neonate’s HIV 
PCR status. Universal early initiation of antiretroviral therapy in 
neonates with HIV may currently be the most effective strategy to 
reduce the risk of both BCG and TB disease in this population. [16] 
HIV co-infection is not uncommon in pregnant women with 
TB.[17] For HIV-exposed neonates receiving nevirapine as part of 
prevention of mother-to-child transmission of HIV treatment and 
requiring TB preventive therapy, TPT with isoniazid for 6 months is 
preferred. Prevention of TB using rifampicin plus isoniazid reduces 
nevirapine concentrations in HIV-exposed infants, potentially 
providing inadequate HIV preventive therapy with a risk of HIV 
seroconversion.[18] An isoniazid dose of 10 mg/kg/d in LBW neonates 
was shown to achieve comparable adult target isoniazid plasma 
concentrations, cautioning against the use of higher isoniazid doses 
in smaller and younger infants with reduced drug elimination.[19]
The management of neonates exposed to drug-resistant TB should 
always be discussed with an expert, as although the same management 
principles apply, the anti-TB medications for preventive therapy 
and treatment differ. In the case of isoniazid mono-resistance, 
rifampicin for 4 months should be used as TPT. For rifampicin 
mono-resistant TB exposure when the source case’s isolate exhibits 
phenotypic susceptibility to isoniazid, isoniazid preventive therapy 
for 6 months should be used; however, with rifampicin-resistant TB 
and unknown or unconfirmed isoniazid susceptibility or multidrug-
resistant TB exposure, an expert should be consulted. TB treatment 
in the neonate with drug-resistant TB disease should be tailored 
to the drug susceptibility test (DST) results of the mother’s (source 
case’s) M. tuberculosis isolate; DST should be done on the neonate’s 
specimen if this is bacteriologically positive. If the mother’s DST 
results are not available, drug-susceptible preventive therapy or 
treatment as appropriate should be started, and bacteriological results 
of both mother’s and infant’s specimens followed up.
Hospital-based evaluation of a symptomatic TB-exposed neonate,
including premature and low-birthweight neonates
TB evaluation
Clinical examination including general, respiratory and abdominal
Chest radiograph (anteroposterior and lateral where feasible)
Abdominal ultrasound if any abdominal distension or hepatosplenomegaly
Specimens* for bacteriology (AFB microscopy, Xpert Ultra and mycobacterial culture)
Lumbar puncture for CSF evaluation if clinically indicated or miliary TB
HIV testing if not yet done
Probable/conrmed TB
Start TB treatment immediately (according to mother's 
or neonate's DST result if available)
Do not give BGC
Give ARVs (prophylaxis or treatment) if indicated
Follow up monthly for dose adjustment and clinical evaluation 
including adverse eects
Give BCG upon completion of treatment if 
TST/IGRA remains negative
Not TB (exposed/infected only)
Start TB preventive therapy (according to mother's 
isolate DST result)
Do not give BCG
Give ARVs (prophylaxis or treatment) if indicated
Follow up monthly for dose adjustment and clinical evaluation 
for TB or adverse eects
If symptoms/signs of TB, re-evaluate TB
Give BCG upon completion of TB preventive therapy
Fig. 1. Algorithm for hospital-based evaluation of a symptomatic neonate exposed to maternal TB. (TB = tuberculosis; AFB = acid-fast bacilli; Xpert Ultra = 
Xpert MTB/RIF Ultra; CSF = cerebrospinal fluid; DST = drug susceptibility testing; ARVs = antiretrovirals; TST = tuberculin skin test; IGRA = interferon-
gamma release assay; *Usually gastric or tracheal aspirates, the latter if intubated.)
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Infection control measures for hospitalised  
TB-exposed neonates
Mothers with TB and their newborns should preferably not be 
separated from each other in the hospital setting, although the 
mother should be isolated with her newborn in the same room if 
both are clinically stable; however, the mother should not be allowed 
in a neonatal ward while infectious. TB treatment should be started 
in the mother, and the neonate should receive preventive therapy or 
treatment according to the clinical decision. Breastfeeding should 
be encouraged, with the mother wearing a face cover if she is still 
infectious.[12] The risk of TB transmission through breastmilk is 
negligible, and insignificant amounts of anti-TB medications are 
excreted in breastmilk, although data for the newer anti-TB drugs are 
awaited. In high TB-burden settings, a TB screening policy should 
be in place where mothers share facilities, such as Kangaroo Mother 
Table 2. Anti-TB regimens for neonates exposed to maternal drug-susceptible tuberculosis
Anti-TB drug(s) 
TB preventive therapy Isoniazid for 6 months, or
Isoniazid plus rifampicin for 3 months
TB treatment Intensive phase
Isoniazid, rifampicin, pyrazinamide, ethambutol for 2 months, or
Isoniazid, rifampicin, pyrazinamide, ethionamide for 2 months
Continuation phase
Isoniazid and rifampicin for 4 - 7 months depending on disease severity and response to treatment
TB = tuberculosis.
Table 3. Anti-TB drug dosages for neonates
Anti-TB drugs Daily dose range (mg/kg)
Isoniazid 7 - 15
Rifampicin 10 - 20
Pyrazinamide 30 - 40
Ethambutol 15 - 25
Ethionamide 15 - 20
TB = tuberculosis.
Table 1. Guidance for the interpretation of hospital-based TB screening investigations
Chest radiograph Should be done regardless of whether symptoms or signs are present. Congenital TB may differ from 
postnatal TB on chest radiograph.[4] Mediastinal nodes, airway compression, bronchopneumonic 
parenchymal infiltrates or a miliary pattern may occur. Also consider TB if pneumonic infiltrates do 
not respond to antibiotics. 
Bacteriological confirmation 
(respiratory specimens such as gastric 
aspirates, tracheal aspirates) and other 
relevant specimens
Smear microscopy for AFB may be of value in neonates who aspirated TB-infected amniotic fluid 
or in infants with uncontained pulmonary TB. Xpert MTB/RIF Ultra is a more sensitive test than 
microscopy and may provide an additional RIF DST result. Mycobacterial culture, although slow, is 
currently still the most sensitive bacteriological test, and important for DST. 
Abdominal ultrasound If abdominal distension or hepatosplenomegaly is present in the absence of any other confirmatory TB 
test, an abdominal ultrasound scan to look for focal lesions in the liver or spleen, or retroperitoneal or 
intra-abdominal lymphadenopathy, as well as ascites, can help to confirm a diagnosis of perinatal TB.[6]
Lumbar puncture for CSF evaluation CSF is often obtained in neonates as part of a septic work-up in early-onset sepsis with a positive 
blood culture or when meningitis is suspected; in the case of a lymphocytic predominance, TB 
meningitis should be considered.[21] If a miliary picture is present on the chest radiograph, a lumbar 
puncture should be done. 
Other investigations
Placenta Histopathological evaluation of placental TB, if the mother is not known to have had TB disease 
during the last trimester of pregnancy, may assist in the diagnosis of TB in the mother.[22]
Endometrial sampling Culture and histological analysis of a maternal endometrial pipelle sample for mycobacteria may be 
done to exclude genital tuberculosis or confirm congenital TB.[23]
TST (Mantoux) Utility of TST in neonates is poor owing to low reactogenicity and poor helper T-cell responses.  
A positive TST is supportive evidence of TB infection or disease, but negative results do not rule  
out the possibility of TB infection or disease.[7]
 Interferon-gamma release assays 
(Quantiferon-TB Gold In-Tube or 
T-SPOT.TB)
Blood tests to confirm TB infection, like TST, are not very sensitive in neonates. They have the 
advantage of being more specific than TST, especially if BCG has been administered.[24]
 Stool sample for Xpert MTB/RIF 
Ultra
Detecting Mycobacterium tuberculosis in stool samples of children using molecular methods is a 
promising non-invasive way of diagnosing pulmonary TB. Limitations include a lack of data on the 
performance of this method in infants and young children.[25]
TB = tuberculosis; AFB = acid-fast bacilli; RIF = rifampicin; DST = drug susceptibility testing; CSF = cerebrospinal fluid; TST = tuberculin skin test.
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Care units, to prevent exposure and transmission of TB to vulnerable 
neonates, mothers and healthcare workers.[20]
Conclusions
There are many challenges in the identification, investigation 
and clinical management of TB-exposed neonates. We propose 
an investigation and treatment algorithm for the hospital-based 
evaluation of symptomatic TB-exposed neonates, including preterm 
and LBW neonates, to guide clinicians to the earlier identification 
and diagnosis of TB infection and disease in SA neonatal practice.
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